Ann: Cellmid Reports on Results of The Doherty Institute Testing, page-67

Yes, CDY's core business is i) their Advangen products; and ii) their midkine IP (Lyramid) relating to treating inflammatory diseases... however, the addition of the SARS-CoV-2 POCT tests to their 'portfolio' and subsequent introducer agreement can't be underestimated here. The threat of a second wave of COVID-19 opens the door to the need scale up testing again, globally. Check out the impact this news had on AT1 yesterday...

Don't get me wrong, core business needs to be their focus, but diversification allows the establishment of new networks / relationships / partnerships in the industry. Further investment from the Board / CEO is a fair indication of their intent for the future of the business.

Also, a lot of talk about the reliability of these tests, but how about the false positive at Essendon using the PCR test...?